

HAIR STUDY

Preliminary Clinical Results
NIH-IDENTIFIED PHASE 1 HUMAN
CLINICAL TRIAL

NIH-IDENTIFIED

STUDY

Methodology

ALPHA VARIN COMPLEX[™] PHASE 1 HUMAN CLINICAL TRIAL

Study Type: Interventional (Clinical Trial) Estimated Enrollment: 40 participants

Allocation: Randomized Primary Purpose: Treatment

Official Title: Androgenetic Alopecia Treatment Using Varin and Cannabidiol-rich Topical Hemp Oil - A Case Series

ClinicalTrials.gov Identifier: NCT04842383

Intervention Model: Parallel Assignment
Intervention Model Description: 40 subjects will be randomly
assigned into two treatment groups, 500mg of cannabinoids
per ounce and 1000mg of cannabinoids per ounce. The change
in hair follicle numbers will be compared statistically between
the two groups.

Masking: Double (Participant, Outcomes Assessor)
Masking Description: The participants in the study and the outcomes assessor on day 0 and day 180 will be prevented from having knowledge of which of the two strengths of cannabinoid topicals were used.

NIH-Identified Phase 1 human clinical trial sponsored by principal investigator, Gregory L. Smith, MD, MPH; and conducted under the guidance of researcher, John Satino, at the Laser Hair Center in Clearwater, FL. The clinical trial measured nonvellus hair counts within a one centimeter square of the subject's area of most significant balding as marked by a tattoo.

Safety & Toxicity:

study.

No adverse reactions were reported by any study participants.

Note: Subjects utilized no hair loss treatments, including

minoxidil and/or finasteride during the six months of the



HAIR STUDY

Preliminary Clinical Results
NIH-IDENTIFIED PHASE 1 HUMAN
CLINICAL TRIAL

NIH-IDENTIFIED

STUDY

Researchers

ALPHA VARIN COMPLEX[™] PHASE 1 HUMAN CLINICAL TRIAL CONDUCTED BY: JOHN SATINO, BS

- Trained in Chinese Acupuncture 1969
- Principal Developer Electro-Acupunture US 1971
- Studied Biomedical Engineering Ohio State University
- Post graduate work, Wright State University, under Dr Gerald Petrowsky, Biomedical Dept. (Reversing Leg Muscle atrophy in Spinal Cord Injuries, with Electronic Muscle Stimulation) - 1977
- Research Director, Biotone Heart Pacemaker Development Division - 1979
- Consultant to NASA's Biomedical Dept., Kennedy Space Center, for the development of EMS to prevent leg muscle atrophy in space - 1983
- Research Coordinator, Upjohn Pharmaceutical, Research & Development of Minoxidil (Rogaine) for hair regrowth -1984
- Research Coordinator, Merck Pharmaceutical Research & Development of Finasteride (Propecia) for hair regrowth -1989
- Medical Advisor to Lexington International, for FDA Clearance using Low Level Laser for hair regrowth
- Published International Journal of Cosmetic Surgery and Aesthetic Dermatology - 2003
- Published National Hair Journal (Laser Wound Healing) -2005
- Memberships; New York Academy of Sciences, American Hair Loss Council, Society for Laser Medicine and Surgery, Laser Institute of America, International Society of Hair Restoration Surgeons
- Laser Safety Officer, Lumenis Laser Company
- Past CEO Biostem US (Publicly Traded Regenerative Medicine Company) - 2005
- Presently, Clinic Director, Laser Hair & Scalp Clinics Clearwater, Florida



HAIR STUDY

Preliminary Clinical Results
NIH-IDENTIFIED PHASE 1 HUMAN
CLINICAL TRIAL

NIH-IDENTIFIED

STUDY

Researchers

ALPHA VARIN COMPLEX[™] PHASE 1 HUMAN CLINICAL TRIAL SPONSORED BY: GREGORY L. SMITH, MD, MPH

- Residency Trained, Board-Certified in Preventive Medicine and Occupational Medicine
- Rush Medical College, Chicago, Illinois
 - Medical Doctor (MD)
- Harvard School of Public Health, Boston, Massachusetts
 - Masters of Public Health (MPH)
- William Beaumont Army Medical Center, El Paso, Texas
 - Flexible Internship May 1983
- Walter Reed Army Medical Center, Washington, D.C.
 - o Residency in General Preventive Medicine June 1985
- Partial List of Publications/Presentations:
 - Hair Regrowth with Cannabidiol (CBD)-rich Hemp
 Extract A Case Series, Cannabis 4: 53-59, 2021
 - Fast Facts: Medical Cannabis and Opioid Weaning
 (220 pages), Springer Press, January 2020
 - Tetrahydrocannabivarin and Endocannabinoid Energy Metabolism, Insurance Medical Directors Annual Meeting, Amsterdam, October 2019
 - CBDplus THCV Weight Loss, Anti-aging, Blood
 Sugar and Lipid Control (171 pages) KDP Publishing,
 October 2018
 - Actuarial Issues with Medical Cannabis Use, American Academy of Insurance Medicine, Seattle, WA, October 2018
 - Antioxidant Nutraceuticals: Preventive and Healthcare Applications (414 pages) Chapter 14 - CRC Press, April 2018
 - CBD: What You Need to Know (245 pages) KDP Publishing, August 2017



HAIR STUDY

Preliminary Clinical Results
NIH-IDENTIFIED PHASE 1 HUMAN
CLINICAL TRIAL

ALPHA VARIN Complex[™] A Complete CB1 Receptor Antagonist


Blocking the human body's CB1 receptors with ALPHA VARIN Complex[™] results in (1) the stimulation of keratinocytes witch results in hair shaft elongation and (2) stimulation of matrix cells which results in thickening of the hair shaft. ALPHA VARIN Complex[™] also stimulates the TRPV1 receptor which lengthens the duration of time the hair shaft is in the telogen, or resting phase, of the growth cycle.

The results in this clinical trial show increases in hair shaft thickness, hair shaft health, and hair counts in the areas of balding.

FINDING 01

Hair Thickness and Health


Using ALPHA VARIN
Complex,™ study
participants experienced
significantly thicker and
healthier hair.



FINDING 02

Hair Counts at Day 0


100% of study participants using ALPHA VARIN
Complex[™] experienced at least 105% increase in new nonvellus hair counts over the 180 day trial.



FINDING 03

Hair Counts at Day 180

Multiple study participants using ALPHA VARIN
Complex[™] experienced an 800%+ increase in new nonvellus hair counts with an average increase per study participant of 371%.



Artist's rendering of study findings. Not to scale.



HAIR STUDY


Preliminary Clinical Results
NIH-IDENTIFIED PHASE 1 HUMAN
CLINICAL TRIAL


ALL-NATURAL ALPHA VARIN COMPLEX[™] INCREASED HAIR COUNTS


Participants used the All-Natural ALPHA VARIN Complex[™] for 180 days. On average, study participants experienced 371% increase in new nonvellus hair counts as measured in the test-count area. The test-count area was a 1cm-square area marked with a tattoo and located in the area of most significant balding.

ALL-NATURAL ALPHA VARIN COMPLEX[™] INCREASED HAIR SHAFT THICKNESS AND HEALTH

Participants used the All-Natural ALPHA VARIN Complex[™] for 180 days. In addition to the significant increases in new novellus hair counts, study participants also experienced a significantly thicker core of the hair shaft and improved healthy appearance of the hair.







Artist's rendering of study findings. Not to scale.



HAIR STUDY

Preliminary Clinical Results
NIH-IDENTIFIED PHASE 1 HUMAN
CLINICAL TRIAL



100% of study
participants using
ALPHA VARIN Complex[™]
experienced at least
105% increase in new
nonvellus hair counts



Upon completion of the study, participants indicated an average 91% satisfaction with the ALPHA VARIN Complex.™

Increased New Nonvellus Hair Counts

On average, study participants using ALPHA VARIN Complex[™] experienced a 371% increase in new nonvellus hair counts as measured in the test-count area.

Improved Hair Thickness and Health Study participants using ALPHA VARIN Complex experienced significantly improved hair thickness and health.

230/n

31%

62º/o

23% of study participants saw new nonvellus hair count increases of at least 8X 31% of study participants saw new nonvellus hair count increases of at least 5X

62% of study participants rated ALPHA VARIN™a perfect 10 out of 10

Virtually all hair restoration products on the market are made from synthetic pharmaceuticals with a multitude of potential sideeffects and warnings for use.

ALPHA VARIN Complex[™] is 100% All-Natural and can be used safely with confidence.

All-Natural ALPHA VARIN hair products are powered by BEVARIN Wellness' proprietary ALPHA VARIN Complex and completely block the body's CB1 receptors leading to incredible hair restoration and increases. For best results and to maintain hair increases, continued use of the product is recommended.



HAIR STUDY

Preliminary Clinical Results



MONTH 1










MONTH 1 PRELIMINARY CLINICAL TRIAL RESULTS SUBJECT 149



ALPHA VARIN Complex™

MONTH 1



MONTH 6



ALPHA VARIN Complex™







HAIR STUDY

Preliminary Clinical Results











HAIR STUDY

Preliminary Clinical Results







